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ABSTRACT
REGULATION OF INTERFERON- INDUCED INTERLEUKIN-8 AND PD-L1
EXPRESSION IN OVARIAN CANCER CELLS
Sveta Padmanabhan

Interferon-γ (IFNγ) is a pleiotropic cytokine that has a crucial role in immune
response and tumor immunity. Because of its anti-tumor effects, IFNγ has been used in
cancer treatment. However, IFNγ also has tumor-promoting functions that are less well
understood. Here, I show that IFNγ induces expression of the pro-inflammatory and proangiogenic chemokine interleukin-8 (IL-8, CXCL8) in ovarian cancer (OC) cells. The
IFNγ-induced IL-8 expression is dependent on JAK1, STAT1, and p65 NFκB, and is
associated with an increased occupancy of K314/ 315 acetylated p65 NFκB and Ser-727
phosphorylated STAT1 at the IL-8 promoter. Neutralization of IL-8 using anti-IL-8
antibody reduces IFNγ-induced migration of OC cells. These findings indicate that the
IFNγ-induced IL-8 expression contributes to IFNγ pro-tumorigenic effects in ovarian
cancer cells. In addition, IFNγ induces expression of immune checkpoint PD-L1 in OC
cells, resulting in their increased proliferation and tumor growth, but the mechanisms that
regulate PD-L1 expression in OC remain unclear. My results demonstrate that the IFNγinduced PD-L1 expression in OC cells is associated with increased levels of STAT1, Tyr701 pSTAT1 and Ser-727 pSTAT1. Suppression of JAK1 and STAT1 significantly
decreases the IFNγ-induced PD-L1 expression in OC cells. In addition, IFNγ induces

expression of the transcription factor interferon regulatory factor 1 (IRF1) and IRF1
suppression attenuates the IFNγ-induced gene and protein levels of PD-L1. Chromatin
immunoprecipitation results show that IFNγ induces PD-L1 promoter acetylation and
recruitment of STAT1, Ser-727 pSTAT1 and IRF1 in OC cells. These findings
demonstrate that the IFNγ-induced PD-L1 expression in OC cells is regulated by JAK1,
STAT1, and IRF1 signaling, and suggest that targeting the JAK1/ STAT1/IRF1 pathway
may provide a leverage to regulate the PD-L1 levels in ovarian cancer. Studying the
molecular mechanisms that regulate expression of IFNγ-induced IL-8 and PD-L1 will
contribute to better understanding of tumor promoting functions of IFNγ
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INTRODUCTION
Interferon-γ (IFNγ) is a pleiotropic cytokine that has a crucial role in immune
responses and tumor immunity [1-4]. IFNγ is produced mainly by activated lymphocytes,
but its expression is also induced in response to radiation therapy or immune checkpoint
blockade used in cancer treatment [5-8]. Because of its anti-tumor effects, IFNγ has been
used in cancer treatment, even though with mixed results [9-15]. Indeed, mounting
evidence indicates that IFNγ also has important tumor-promoting functions [16-23].
Understanding the tumor-promoting mechanisms and molecular targets of IFNγ is
important to minimize its tumor-promoting functions in IFNγ based therapies, and in
cancer treatments associated with IFNγ increase.
IFNγ signals primarily via the Janus kinase (JAK)/Signal transducer and activator
of transcription (STAT) pathway to induce expression of interferon stimulated genes
(ISGs) [24-26]. Binding of IFNγ to its receptors IFNγR1 and IFNγR2 triggers a signaling
cascade, in which activated JAK phosphorylates STAT1 at Tyr701 residue.
Phosphorylated STAT1 then dimerizes and translocates to the nucleus, where it binds to
specific gamma activated sequences (GAS), resulting in transcription of ISGs [24-26]. In
some cells, STAT1 is phosphorylated also at Ser727, which enhances its transcriptional
activity [27, 28]. In addition, IFNγ induces expression of the transcription factor
interferon regulatory factor 1 (IRF1), potentially enabling its interaction with STAT1 and
binding of the STAT1-IRF1 complexes to the GAS elements [3, 29].
Interleukin-8 (IL-8, CXCL8) is a pro-inflammatory and pro-angiogenic
chemokine that has a crucial role in cancer progression through its induction of tumor cell
proliferation, migration, invasion, immune escape, and metastasis [30-34]. Serum IL-8
1

levels are increased in patients with solid tumors, reflect the tumor burden, and correlate
with poor prognosis [35, 36]. In most cells, the IL-8 expression is regulated by the
transcription factor NFB, particularly by p65 homodimers [37-39]. However,
understanding the mechanisms that regulate the IL-8 expression in tumors has been
lagging since mice do not have the IL-8/CXCL8 gene [40]. It has been recently shown
that IFNγ promotes proliferation and migration of ovarian cancer (OC) cells [41, 42].
Considering the strong pro-proliferative and pro-migratory effects of IL-8, in this study I
tested the hypothesis that the IFNγ-induced migration of OC cells might be mediated by
IL-8.
Interestingly, recent studies have shown that elevated serum levels of IL-8
correlate with reduced responses to programmed death ligand-1 (PD-L1, CD274) /
programmed death -1 (PD-1) checkpoint blockade in cancer patients and that low IL-8
serum levels correlate with overall survival in cancer patients undergoing anti PD-1/PDL1 therapy, suggesting a link between IL-8 and PD-L1 expression in cancer patients [35,
36, 43-45]. High expression of the immune checkpoint PD-L1 in solid tumors, including
ovarian cancer inhibits T cell-mediated antitumor responses, thus promoting tumor
immune evasion, cancer progression, and metastasis [46-50]. In addition, PD-L1 has
immune independent, cell intrinsic functions that include increased cancer cell
proliferation, cell survival, mTOR signaling, DNA damage response, and development of
cisplatin resistance [51-55]. Understanding the mechanisms that regulate the PD-L1
expression in cancer cells is required to modulate the PD-L1 levels and the associated
cancer cell functions, but the mechanisms that regulate the PD-L1 expression in OC cells
remain largely unknown.
2

The expression of PD-L1 in cancer cells, including OC, is upregulated by type II
interferon, IFNγ [4, 16]. It has been recently shown that the IFNγ-induced PD-L1
expression in OC cells is mediated by the proto-oncogene Bcl3 and by p65 NFB,
resulting in the increased proliferation and migration of OC cells [41, 42]. In this study, I
have investigated the role of JAK1/STAT1 signaling in the IFNγ-induced PD-L1
expression in OC.
This study demonstrates that IFNγ induces the expression of IL-8 and PD-L1 in
OC cells. IFNγ induced IL-8 and PD-L1 levels are regulated by JAK1/STAT1 signaling
pathway. In addition, IL-8 is also regulated by p65 NFB, and mediates IFNγ induced
migration of OC cells. IFNγ induces occupancy by p65 NFB and Ser727 pSTAT1 at the
IL-8 promoter and occupancy by STAT1, Ser727 pSTAT1 and IRF1 at the PD-L1
promoter. Together, this study identifies the mechanisms that regulate the IFNγ induced
IL-8 and PD-L1 expression in OC cells, and may lead to development of novel IFNγbased combination anti-cancer strategies
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MATERIALS AND METHODS

Cell culture
Human ovarian cancer SKOV3 and OVCAR3 cells were obtained from the
American Type Culture Collection (ATCC; Rockville, MD). Cells were cultured (5x10 5
cells/ml) in 6-well plates in RPMI 1640 medium (Invitrogen, Grand Island, NY)
supplemented with 10 % heat inactivated fetal bovine serum (FBS; Invitrogen, Grand
Island, NY) and antibiotics at 37°C with 5% CO2. For treatment with IFNγ, human
recombinant IFNγ (285-IF-100; R&D Systems, Minneapolis, MN) was reconstituted in
sterile water. Cell viability was measured by using Trypan Blue exclusion.

Transfection with siRNA
Human JAK1 (sc-35719), STAT1 (sc-44123), IRF1 (sc-35706), p65 (sc-29410)
and non-silencing (sc-37007) small interfering RNAs (siRNA) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Prior to transfection, 2 × 10 5 SKOV3 cells were
seeded into a 6-well plate and incubated in a humidified 5% CO2 atmosphere at 37°C in
antibiotic-free RPMI medium supplement with 10% FBS for 24 hours to about 80%
confluence. For each transfection, 80 pmol of either non-silencing control siRNA or
respective siRNA were used. Cells were transfected 6 hours in siRNA transfection
medium with siRNA transfection reagent according to manufacturer’s instructions (Santa
Cruz Biotechnology). After transfection, fresh medium with antibiotics was added, and
the cells were grown for 24 hours before treatment.
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Real time RT-PCR
Total RNA was isolated by using RNeasy mini-kit (Qiagen, Valencia, CA). The
iScript one-step RT-PCR kit with SYBR Green (Bio-Rad, Hercules, CA) was used as a
supermix and 20 ng/µl of RNA was used as template on a Bio-Rad MyIQ Single Color
Real-Time PCR Detection System (Bio-Rad). The primers used for quantification of
human IL-8, JAK1, STAT1, IRF1, PD-L1 and actin mRNA were purchased from Qiagen
(Germantown, MD). The mRNA values are expressed as a percentage of control or
untreated (UT) samples, which were arbitrarily set as 100%.

ELISA
Human IL-8/CXCL8 release was measured by a commercially available ELISA
kit (R&D, Minneapolis, MN, USA).

Western analysis
Denatured proteins were separated on 12% denaturing polyacrylamide gels and
transferred to nitrocellulose membrane (Hybond C; Amersham, Arlington Heights, IL).
Membranes were blocked with a 5% (w/v) nonfat dried milk solution containing 10 mM
Tris-Cl, pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, and 0.1% Tween 20 (TBSTM), and
incubated with PD-L1 (E1L3N; Cell Signaling, Danvers, MA), JAK1 (#66466-1-Ig;
Proteintech), STAT1 (#9172; Cell Signaling), p65 NFκB (sc-8008; Santa cruz
Biotechnology), K314/315 ac-p65 NFκB (HW136; Signalway Antibody), Tyr701pSTAT1 (#7649; Cell Signaling), Ser727-pSTAT1 (#8826S; Cell Signaling), IRF1 (sc74530; Santa Cruz Biotechnology), or actin (A5060-200 UL; Sigma) antibodies diluted in
TBSTM. After washing, the membranes were incubated with HRP-labeled secondary
5

anti-rabbit (Novus NB7185) or anti-mouse (Novus NB7570) antibodies (dilution 1:5000)
and the labeled proteins were detected using the ECL detection system (Amersham,
Arlington Heights, IL). To confirm equivalent amounts of loaded proteins, the
membranes were stripped and re-probed with control anti-actin antibody.

Flow cytometry analysis of surface PD-L1 expression
Flow cytometry analysis was performed as described [56]. Briefly, SKOV3 cells
were grown up to 70-80% confluence for the following treatments for 48h: No antibody,
Control IgG and secondary antibody, PD-L1 antibody and secondary antibody, PD-L1
antibody and secondary antibody with IFNγ treatment. Then, cells were detached using
pre-warmed Accutase™ Cell Detachment Solution, and RPMI media was used to
neutralize the Accutase™ solution. Cells were checked under the microscope to confirm
the presence of unclumped single cells. After centrifugation, the cells were washed in
HBSS solution followed by a wash with Incubation Buffer. This was followed by cell
incubation with PD-L1 antibody (Cell Signalling #86744) or Control IgG (Cell Signalling
#3900S) for 1 hour. After incubation, the cells were washed twice with incubation buffer
with a 10 minute incubation on ice after each wash. Then secondary antibody (Cell
Signalling #4412) was added to the cells and cells were incubated for 1 hour. Following
this, the cells were washed twice with incubation buffer with a 10 minute incubation on
ice after each wash. The cells were then resuspended in incubation buffer to a
concentration of 7 X 105 – 1 X 106 cells/mL and samples were analyzed by flow
cytometry. PD-L1 expression was quantified by measuring the increase in fluorescence
intensity in treated samples compared with untreated cells.
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Cell migration assay
The cell migration transwell assay was performed as described by the
manufacturer’s protocol (Corning, NY, USA). SKOV3 cells were seeded onto the
Corning Biocoat Matrigel Chambers (Corning #354480) at a density of 25,000 cells/0.5
mL in serum-free RPMI medium, with bottom wells containing RPMI medium with 10%
FBS. Cells in the top chambers were incubated with recombinant human IFNγ (0 and 50
ng/mL; R&D Systems, 285-IF-100) in the presence of IL-8 neutralizing monoclonal
antibody (2 μg/mL; R&D, MAB208) or control IgG (2 μg/mL; Santa Cruz
Biotechnology; sc-2025) for 24 h. After incubation, non-migrating cells were scrubbed
from the upper surface of the top chambers using cotton swabs. Migrating cells on the
bottom membranes were fixed with 100% methanol, stained with crystal violet, washed,
and air dried. Migrating cells were counted in five randomly selected fields under a
phase-contrast microscope at 10 × magnification, and quantified using ImageJ software
as described [57].

Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed as described [58]. Briefly, proteins and DNA were
cross-linked by formaldehyde, and cells were washed and sonicated. The lysates were
centrifuged (15,000 g, 10 min, 4 °C), and the supernatant extracts were diluted with ChIP
dilution buffer and pre-cleared with Protein A/G Agarose (sc-2003; Santa Cruz
Biotechnology) for 1 hour at 4 °C. Immunoprecipitations were performed overnight at 4
°C, using p65 (Sigma, MAB3026), K314/315 ac-p65 (Signalway Antibody, HW136),
STAT1 (#9172; Cell Signaling), Ser727-pSTAT1 (#8826S; Cell Signaling), IRF1 (sc74530; Santa Cruz Biotechnology), histone H3 (ab1791; Abcam), and Lys9 ac-histone
7

H3 (#9649; Cell Signalling) antibodies. Following immunoprecipitation, the samples
were incubated with Protein A/G Agarose (overnight, 4 °C), and the immune complexes
were collected by centrifugation (150 g, 5 min, 4 °C), washed, and extracted with 1%
SDS–0.1 M NaHCO3. After reversing the cross-linking, proteins were digested with
proteinase K, and the samples were extracted with phenol/chloroform, followed by
precipitation with ethanol. The pellets were re-suspended in nuclease-free water and
subjected to real time PCR. Immunoprecipitated DNA was analyzed by real-time PCR
(25 µl reaction mixture) using the iQ SYBR Green Supermix and the Bio-Rad MyIQ
Single Color Real-Time PCR Detection System (Bio-Rad). Each immunoprecipitation
was performed at least three times using different chromatin samples, and the occupancy
was calculated by using negative control primers, which detect specific genomic ORFfree DNA sequence that does not contain any binding sites for any known transcription
factors. The results were calculated as a fold difference in p65, Ac-p65, STAT1, Ser727pSTAT1, IRF1, histone H3, and ac-histone H3 occupancy at the STAT1 and IRF1
binding sites compared to the control negative locus that does not bind any transcription
factors.
The IRF1 primers used for real time PCR were as follows: IL-8-STAT1 forward,
5’- -TTTGAAAAGTTGTAGTATGCCCC -3’ and reverse, 5’AGAGTGGCAGGTGTTAGAAC -3’ ; IL-8- NFκB forward, 5’TGGGCCATCAGTTGCAAATC -3’ and reverse, 5’- AGTGAGATGGTTCCTTCCGG3’. The PD-L1 primers used for real time PCR were as follows: PDL1-STAT1 forward,
5’- TGGGTCTGCTGCTGACTTTTTA-3’ and reverse, 5’AGAGGGGTAAGAGCTTAAGGTTAC-3’; PD-L1-IRF1 forward, 5’-
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TTCCCGGTGAAAATCTCATT -3’ and reverse, 5’- GGTATCTAGTGTTGGTGTCC 3’.

Statistical analysis
The results represent at least three independent experiments. Numerical results are
presented as means ± SE. Data were analyzed by using an InStat software package
(GraphPAD, San Diego, CA). Statistical significance was evaluated by using one-way
ANOVA Tukey-post Hoc-test, and p<0.05 was considered significant.
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SPECIFIC AIMS
Aim 1: Test the hypothesis that IFNγ induces expression of IL-8 in OC cells.
Aim 2: Analyze whether the IFNγ induced migration of OC cells is mediated by IL-8.
Aim 3: Investigate the role of JAK/STAT/p65 NFB signaling in the IFNγ-induced IL-8
expression in OC cells.
Aim 4: Investigate the role of JAK/STAT IRF1 signaling in the IFNγ-induced PD-L1
expression in OC cells.
Aim 5: Determine the specific mechanisms how IFNγ induces the IL-8 and PD-L1
expression in OC cells.
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RESULTS
IFNγ induces IL-8 expression and cytokine release in OC cells
Our recent studies have shown that IFNγ induces proliferation and migration of
OC cells [41, 42]; thus, I investigated the possibility that IFNγ might promote expression
of the pro-angiogenic chemokine IL-8. As shown in Fig. 1, incubation of ovarian cancer
SKOV3 and OVCAR3 cells for 48 hours with IFNγ dose-dependently increased the IL-8
gene expression (Fig. 1A) and cytokine release (Fig. 1B) in both types of OC cells. The
IFNγ-induced IL-8 expression in OC cells was also time-dependent; significant IL-8
mRNA (Fig. 1C) and cytokine release (Fig. 1D) levels were induced 24 hours after
stimulation with 50 ng/mL IFNγ.

IFNγ induces STAT1 signaling in OC cells
Since IFNγ signals primarily via the JAK1/STAT1 pathway [24-26], I analyzed
whether IFNγ induces STAT1 signaling in OC cells. As shown in Fig. 2 A-D, IFNγ (50
ng/mL) greatly increased STAT1 mRNA and protein levels in ovarian cancer SKOV3
and OVCAR3 cells. However, in the absence of IFNγ, unstimulated SKOV3 and
OVCAR3 cells expressed only low protein levels of STAT1 (Fig. 2 C, D). Within 30 min
after stimulation, IFNγ induced a robust but transient phosphorylation of STAT1 at
Tyr701 in both OC cells (Fig. 2 C, D). In addition, IFNγ induced STAT1
phosphorylation at Ser727; however, in contrast to Tyr701 phosphorylation, STAT1
phosphorylation at Ser727 gradually increased and was sustained 48 h after IFNγ
stimulation (Fig. 2 C, D).
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IFNγ-induced IL-8 expression is mediated by JAK1/STAT1 signaling
The primary pathway by which IFNγ induces gene expression is the JAK1STAT1 canonical pathway [24]; thus, I investigated whether the IFNγ-induced IL-8
expression is regulated by JAK1/STAT1 signaling. The IL-8 expression was first
analyzed in SKOV3 cells transfected with control and JAK1 si RNA. As shown in Figs.
3A and B, IFNγ increased the cellular levels of JAK1, which were suppressed by JAK1
si RNA. Importantly, suppression of JAK1 significantly decreased the IFNγ-induced IL-8
expression in SKOV3 cells (Fig. 3C).
Since IFNγ signaling induces activation of the transcription factor STAT1 [24], I
next analyzed STAT1 involvement in the IFNγ-induced IL-8 expression. As shown in
Figs. 4A and B, IFNγ increased the cellular levels of STAT1 in SKOV3 cells, and the
IFNγ-induced STAT1 expression was suppressed in cells transfected with STAT1
siRNA. Importantly, suppression of the IFNγ-induced STAT1 resulted in a significantly
reduced IL-8 expression (Fig. 4C). Together, these results demonstrate that the IFNγinduced IL-8 expression is mediated by the JAK1/STAT1 signaling.

IFNγ-induced IL-8 expression is mediated by p65 NFB signaling
Since in most cells, the IL-8 transcription is regulated by NFB, particularly by
p65 homodimers [37-39], I have also evaluated the IL-8 expression in cells transfected
with p65 siRNA. IFNγ increased p65 expression, which was suppressed by p65 siRNA in
IFNγ-stimulated SKOV3 cells (Figs. 5A and B). The IFNγ-induced IL-8 mRNA levels
were significantly suppressed in cells transfected with p65 specific siRNA (Fig. 5C),
indicating that the IFNγ-induced IL-8 expression in OC cells is also regulated by p65
signaling
12

IFNγ induces K314/315 ac-p65 and Ser727 p-STAT1 recruitment to IL-8 promoter
The transcriptional activity of p65 NFB is regulated by its acetylation on Lys
314/315 [59-61]; thus, I have analyzed whether IFNγ increases K314/315 acetylation
levels in OC cells. In addition, because Ser-727 phosphorylation of STAT1 is required
for its full transcriptional and biological activity [24], I have examined whether IFNγ
induces STAT1 Ser-727 phosphorylation. To this end, SKOV3 cells were incubated with
IFNγ for 0, 6, 24 and 48 hours, and total cellular levels of p65, K314/315 ac-p65, STAT1,
Ser727-pSTAT1, and control actin were analyzed by western blotting. As shown in Fig.
6A, while IFNγ increased the total cellular levels of p65 at 24 and 48 hours, the levels of
K314/315 ac-p65 were not increased. However, IFNγ increased the cellular levels of
Ser727-pSTAT1, as well as the total levels of STAT1 in SKOV3 cells (Fig. 6A).
IFNγ-activated STAT1 binds to consensus GAS (IFN-γ-activated sequence)
motifs (TTCCNNNAA) [24]. I analyzed the human IL-8 promoter and identified a
potential GAS binding motif (TTCCTAGAA) located -490 bp from the transcription start
site (TSS; Fig. 6B). To determine whether STAT1 binds to this site in OC cells, I
measured the recruitment of STAT1 and Ser727-pSTAT1 to IL-8 promoter in IFNγtreated SKOV3 cells by chromatin immunoprecipitation (ChIP), which measures
transcription factor occupancy at endogenous promoter binding sites. In addition, I
investigated recruitment of p65 and K314/315 ac-p65 to this potential STAT1 binding
site, as well as to the NFB binding site located -82 bp from TSS. While I did not detect
any substantial recruitment of STAT1, Ser727-pSTAT1, p65, or K314/315 ac-p65 to the
STAT1 binding motif in IFNγ-stimulated SKOV3 cells (Fig. 6C, left panel), I found that
IFNγ induced K314/315 ac-p65 recruitment to the NFB binding site at 6 hours, and
Ser727 pSTAT1 recruitment to the NFB site at 24 and 48 hours (Fig. 6C, right panel).
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The fact that IFNγ induces IL-8 promoter occupancy by K314/315 ac-p65 (Fig. 6C),
while it does not increase the cellular levels of K314/315 ac-p65 (Fig. 6A) suggests that
IFNγ does not induce p65 acetylation, but rather increases recruitment of K314/315 acp65 to the NFB binding site in IL-8 promoter. Together, these results indicate that the
IFNγ-induced IL-8 expression in OC cells is regulated by a direct recruitment of both
K314/315 ac-p65 NFB and Ser727 pSTAT1 to IL-8 promoter.

Neutralization of IFNγ-induced IL-8 inhibits migration of OC cells
Considering that an increased expression of IL-8 promotes migration and tumor
growth in solid cancers [30-32], I hypothesized that the IFNγ-induced IL-8 release in OC
cells might contribute to the tumor-promoting functions of IFNγ. To test this hypothesis,
I first analyzed migration of OC cells stimulated with IFNγ in the presence of IL-8
neutralizing antibody or control IgG, using the trans-well assay. As shown in Fig. 7,
incubation of OC cells with IFNγ significantly increased their migration. Importantly,
neutralization of IL-8 by IL-8 neutralizing antibody suppressed the IFNγ-induced OC cell
migration (Fig. 7), indicating that the IFNγ-induced migration of OC cells is partly
mediated by the IFNγ-induced IL-8.

IFNγ induces surface PD-L1 expression in OC cells
IFNγ induces PD-L1 expression in human OC cells, resulting in their increased
proliferation and migration [16, 41, 42, 56, 62]. As shown in Fig. 2 A-D, IFNγ (50
ng/mL) greatly increased PD-L1 mRNA and protein levels in ovarian cancer SKOV3 and
OVCAR3 cells. However, in the absence of IFNγ, unstimulated SKOV3 and OVCAR3
cells expressed only low protein levels of PD-L1 (Fig. 2 C, D). Since surface PD-L1
14

interacts with PD-1 expressed on T cells, I analyzed whether IFNγ induces expression of
surface PD-L1 in OC cells. As compared to control untreated cells incubated with PD-L1
antibody and secondary antibody, IFNγ treated cells show high expression of surface PDL1 (Fig. 8 A, B ). Isotype matched control IgG is used as a control antibody. The relative
surface expression of PD-L1 is about 27 fold higher in IFNγ treated cells as compared to
control untreated cells (Fig. 8 B). Together this data demonstrates that IFNγ induces
gene, protein, and surface expression of PD-L1 in OC cells

IFNγ induced PD-L1 expression in OC cells is dependent on JAK1, which mediates
Tyr701 STAT1 phosphorylation
Since Tyr701 phosphorylation of STAT1 is mediated by the JAK1 kinase [24-26],
I analyzed whether the IFNγ-induced PD-L1 expression in OC cells is dependent on
JAK1. As shown in Fig. 9, suppression of JAK1 by siRNA significantly decreased the
IFNγ‐induced PD‐L1 mRNA and protein levels in OC cells, compared to cells transfected
with control siRNA. Furthermore, JAK1 suppression greatly decreased the IFNγ-induced
STAT1 phosphorylation at Tyr701, while it did not have a substantial impact on Ser727
phosphorylation or the total protein levels of STAT1 in IFNγ stimulated OC cells (Fig.
9C). These data show that JAK1 mediates the IFNγ‐induced STAT1 Tyr701
phosphorylation and PD‐L1 expression in OC cells.

IFNγ induced PD-L1 expression in OC cells is dependent on STAT1
STAT1 expression is increased in OC tumors and correlates with PD-L1
expression [63, 64]. Since my data showed that IFNγ induces STAT1 expression and
phosphorylation in OC cells (Fig. 10), I wanted to determine whether the IFNγ-induced
15

PD-L1 expression in OC cells is dependent on STAT1. As shown in Figs. 10 A and B,
STAT1 suppression by siRNA significantly decreased the IFNγ induced PD-L1 gene
expression 24 and 48 h after IFNγ stimulation. In addition, STAT1 suppression
significantly reduced the PD-L1 protein levels in OC cells stimulated with IFNγ for 24
and 48 h (Figs. 10 C, D), demonstrating that the IFNγ‐induced PD‐L1 expression in OC
cells is dependent on STAT1.

IFNγ induced PD-L1 expression in OC cells is dependent on IRF1
Since the transcription factor IRF1 is involved in IFNγ signaling and regulation of
immune genes [3, 65], I analyzed whether the IFNγ-induced PD-L1 expression in OC
cells was dependent on IRF1. As shown in Figs. 11A and B, IRF1 suppression by siRNA
significantly decreased the IFNγ-induced PD-L1 gene expression 6 and 24 h after IFNγ
stimulation. Furthermore, IRF1 suppression reduced the PD-L1 protein levels 6 and 24 h
after cell stimulation with IFNγ (Figs. 11C, D). Together, these results indicate that
during the early time points, the IFNγ‐induced PD‐L1 expression in OC cells is
dependent on IRF1.

IFNγ induces PD-L1 promoter acetylation and occupancy by STAT1, Ser727pSTAT1, and IRF1 in OC cells
My data showed that the IFNγ-induced PD-L1 expression in OC cells is
dependent on the transcription factors STAT1 (Fig. 10) and IRF1 (Fig. 11). Thus, I tested
whether IFNγ induces recruitment of STAT1 and IRF1 to endogenous PD-L1 promoter in
OC cells. In addition, since Ser727 phosphorylation enhances STAT1 transcriptional
activity [27, 28], I analyzed whether IFNγ induces the PD-L1 promoter occupancy by
16

Ser727-pSTAT1. The human PD-L1 promoter contains putative binding sites for STAT1
(TTATCAGAA) located at position -369 upstream from transcription start site (TSS) and
IRF1 (TGTTTCACTTTC) located at position -162 upstream from the TSS (Fig. 12A).
To analyze whether the IFNγ-induced PD-L1 expression in OC cells is associated with a
promoter recruitment of STAT1, Ser727-pSTAT1, and IRF1, I measured the PD-L1
promoter occupancy by STAT1, Ser727- pSTAT1, IRF1, histone H3, and acetylated (ac)
histone H3 in IFNγ stimulated SKOV3 cells by chromatin immunoprecipitation (ChIP).
As shown in Fig. 12B, IFNγ stimulation significantly increased occupancy of the STAT1
binding site by Ser727-pSTAT1, IRF1, and ac-histone H3. In addition, IFNγ increased
recruitment of total STAT1, Ser727-pSTAT1, and IRF1 to the IRF1 site in PD-L1
promoter (Fig. 12C). Together, these results indicate that IFNγ induces PD-L1
transcription in OC cells by increasing acetylation of the PD-L1 promoter, and
recruitment of STAT1, Ser727 pSTAT1 and IRF1.
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DISCUSSION
My data shows that IFNγ induces the STAT1 signaling in OC cells. IFNγ induces
the expression of IL-8 and PD-L1 in OC cells and IFNγ induced IL-8 and PD-L1
expression is mediated by JAK1/STAT1 signaling in OC cells. In addition, p65 NFB
also mediates IFNγ induced IL-8 expression. Importantly, neutralization of IFNγ induced
IL-8 reduces the IFNγ induced migration of OC cells. IFNγ induces promoter occupancy
by p65 NFB and Ser727 pSTAT1 at the IL-8 promoter, and by STAT1, Ser727 pSTAT1
and IRF1 at the PD-L1 promoter. Understanding the tumor-promoting mechanisms and
molecular targets of IFNγ is important for development of more effective IFNγ-based
combination anti-cancer strategies.
IFNγ is a type II interferon that can have, depending on cellular and molecular
context, both anti-tumor functions and pro-tumorigenic effects [1-4, 62, 66-68]. The antitumor properties of IFNγ include an upregulated expression of MHC proteins on cancer
cells, resulting in their increased recognition by T cells. In addition, IFNγ induces cell
cycle arrest and apoptosis in cancer cells [1, 2]. Because of these anti-tumor effects, IFNγ
has been used in cancer treatment [1-4]. However, most clinical trials using IFNγ in
cancer treatment have produced disappointing results [9-15]. Indeed, recent studies have
indicated that IFNγ also has important tumor-promoting functions that include its ability
to induce expression of immune checkpoints and T cell exhaustion, and increase cancer
cell survival and proliferation [16-23]. Nevertheless, because of its anti-tumor potential,
IFNγ is currently used in clinical trials for the treatment of ovarian, breast, and other solid
cancers (NCT02948426; NCT03112590; NCT02614456). It is critical to study the
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molecular mechanisms of expression of IFNγ induced IL-8 and PD-L1 for better
understanding of the tumor promoting functions of IFNγ.
This study identifies IL-8 as a novel target of IFNγ signaling in solid cancer cells,
and suggests that the IFNγ-induced IL-8 expression contributes to tumor-promoting
effects of IFNγ. The induction of IL-8 expression by IFNγ is consistent with the
dependency of IL-8 expression in IFNγ-stimulated cells on JAK1/STAT1 signaling (Figs.
3, 4), as the JAK1/STAT1 pathway is the primary mechanism regulating expression of
IFNγ-stimulated genes (ISG). However, my results show that the IFNγ-induced IL-8
expression in OC cells is also dependent on p65 NFB (Fig. 5), and suggest a
cooperation between STAT1 and p65 NFB signaling in the transcriptional regulation of
ISG in OC cells. My data indicate that IFNγ first induces IL-8 promoter occupancy by
K314/315 acetylated p65 NFB, followed by recruitment of Ser727 pSTAT1, the
activated form of STAT1 (Fig. 6). Indeed, numerous studies have demonstrated a
crosstalk between NFB and STAT1 signaling pathways in the regulation of IFNγinduced inflammatory genes [69-76].
Interleukin-8, originally discovered as the neutrophil chemoattractant and inducer
of leukocyte-mediated inflammation, promotes tumor progression through its induction
of cancer cell proliferation, migration, invasion, and metastasis [30-34]. IL-8 serum
levels are increased in patients with advanced solid tumors, including ovarian cancer, and
correlate with higher tumor stage, grade, and tumor burden [35, 36]. Interestingly, recent
studies have indicated that increases in IL-8 serum levels may be predictive of resistance
to immune checkpoint inhibitors (ICIs) therapy [43-45, 77]. Since ICIs therapy induces
IFNγ [6-8], it seems likely that one of the underlying mechanisms consists of the IFNγ19

induced IL-8 expression. In this context, it would be important to determine whether
IFNγ used in the current clinical trials increases the IL-8 levels in cancer patients.
Targeting the IL-8 axis might provide an effective strategy in IFNγ-based cancer
treatments and immunotherapies inducing IFNγ expression. The recent clinical trial
NCT02536469 in patients with metastatic solid tumors demonstrated that a human
monoclonal antibody neutralizing IL-8 (HuMax-IL8) is safe and well-tolerated and
suggested the use of anti-IL-8 antibody with other agents [78].
The pro-tumorigenic functions of IFNγ also consists of the IFNγ-induced PD-L1
expression. The IFNγ-induced PD-L1 represses functions of activated T cells in ovarian
tumors, resulting in immune evasion and tumor progression [16]. In addition, PD-L1 has
T cell independent, tumor intrinsic functions that include increased cell survival, mTOR
signaling, and proliferation of OC cells [51-55]. Thus, understanding the mechanisms of
how IFNγ induces the PD-L1 expression in OC cells is essential to regulate the cancer
cell functions controlled by PD-L1. My results show that IFNγ induces expression of
STAT1 and its Tyr-701 and Ser-727 phosphorylation, resulting in PD-L1 expression in
OC cells. In addition, IFNγ induces acetylation of the PD-L1 promoter in OC cells, and
the recruitment of STAT1, Ser-727 pSTAT1 and IRF1. Together, these findings
demonstrate that the IFNγ-induced PD-L1 expression in OC cells is regulated by JAK1,
STAT1, and IRF1 signaling.
Human PD-L1 promoter has binding sites for the transcription factors Myc,
hypoxia-inducible factors HIF1a/2a, AP-1, IRF1, STAT1, STAT3, and NFB. It has been
recently shown that IFNγ-induced PD-L1 expression in OC cells is mediated by the
proto-oncogene Bcl3 and by p65 NFB [41]. In addition, a recent study has found that
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the IFNγ-induced PD-L1 expression in ovarian carcinoma cells is mediated by c-Myc
[79]. However, to my knowledge, this is the first study demonstrating that the IFNγinduced PD-L1 expression in OC cells is regulated by STAT1 and IRF1 signaling. My
results show that while the maximum STAT1 protein expression is achieved 24-48 h after
IFNγ stimulation (Figs. 2, 10), the maximum protein synthesis of IRF1 is achieved within
6 h after stimulation (Fig. 11). These data are consistent with the results demonstrating
the dependence of PD-L1 expression on STAT1 and IRF1 (Figs. 10, 11): STAT1
suppression attenuates the IFNγ-induced PD-L1 expression 24 and 48 h after IFNγ
stimulation (Fig. 10), while IRF1 suppression attenuates the PD-L1 expression induced 6
and 24 h after stimulation (Fig. 11). These results indicate that whereas IRF1 drives the
early PD-L1 expression, STAT1 facilitates the IFNγ-induced PD-L1 expression at later
time points in OC cells. Interestingly however, this study shows that that IFNγ induces
PD-L1 promoter occupancy by both total STAT1/Ser727-pSTAT1 and IRF1 during the
entire course of IFNγ stimulation (Fig. 12), even during time points when PD-L1 is not
regulated by the particular transcription factor. These data suggest that IFNγ might
induce a cooperative association between STAT1 and IRF1 in OC cells; even though
IRF1 does not directly regulate the IFN-induced PD-L1 expression at later time points, it
might be present in the transcriptional complex with STAT1 when STAT1 takes over the
transcriptional regulation of PD-L1. In addition, it is possible that IRF1 has a different
binding affinity for unphosphorylated and phosphorylated forms of STAT1, which might
have different biological functions. Indeed, a previous study has shown that
unphosphorylated STAT1 binds to IRF1 to induce a gene-specific transcription [80].

21

Consistent with other studies that demonstrated that IFNγ activates JAK1 that
phosphorylates STAT1 on Tyr701 [29, 81], my results show that IFNγ quickly induces
STAT1 Tyr701 phosphorylation in OC cells, and this is dependent on JAK1 (Figs. 2, 9).
Importantly, my data demonstrate that the JAK1-mediated Tyr 701 phosphorylation of
STAT1 in OC cells is required for the IFNγ-induced PD-L1 expression (Fig. 9). Since
STAT1 activation induced by Tyr701 phosphorylation in OC cells has been associated
with a development of cisplatin resistance [82], the IFNγ-induced PD-L1 expression
might represent a link between the STAT1 Tyr701 phosphorylation and cisplatin
resistance in OC cells. In contrast to JAK1 that phosphorylates STAT1 on Tyr701,
several kinases have been associated with Ser727 STAT1 phosphorylation in different
cells. These kinases include the cyclin-dependent kinase 8 (CDK8) [83, 84] and casein
kinase 2 (CK2) [85, 86]. However, my data indicate that CDK8 and CK2 are not
responsible for the IFN-induced Ser727 STAT1 phosphorylation and PD-L1 expression
in OC cells, since CDK8 or CK2 inhibition did not have any impact on STAT1
phosphorylation or PD-L1 expression (data not shown).
The PD-L1 expression is increased in ovarian cancer and correlates with poor
prognosis [50, 62]. Recent studies have shown that expression of STAT1 is also
increased in OC tissues, and correlates with IFNγ levels and with the PD-L1 expression
[64, 87]. Furthermore, the recent study of Tian et al has demonstrated increased levels of
Tyr701-pSTAT1 and Ser727-pSTAT1 in OC tissues [63]. My findings show that IFNγ
increases STAT1, Tyr701-pSTAT1 and Ser727-pSTAT1 levels in OC cells, resulting in
the increased PD-L1 expression. In addition to STAT1, the induced PD-L1 expression is
dependent on JAK1 and IRF1 in OC cells.
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In summary, my data demonstrates that IFNγ induces IL-8 and PD-L1 expression
in ovarian cancer cells, resulting in their increased migration. IFNγ induced IL-8
expression is regulated by both the canonical JAK1/STAT1 pathway and NFB
signaling. Since both IFNγ and IL-8 neutralizing antibody have been clinically used in
cancer patients, neutralizing the IFNγ-induced IL-8 might increase IFNγ effectiveness in
cancer treatment. In addition, my data also demonstrates that the IFNγ-induced PD-L1
expression in OC cells is regulated by JAK1, STAT1, and IRF1 signaling, indicating that
targeting the JAK1/ STAT1/IRF1 pathway may provide a leverage to regulate the PD-L1
levels and PD-L1-regulated OC cell functions in ovarian cancer.
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Figure 1. IFNγ induces IL-8 expression in OC cells
(A) Real time qRT-PCR analysis of IL-8 mRNA levels and (B) ELISA of IL-8 cytokine
release in OC cells (5x105 cells/mL) incubated 48 hours with human recombinant IFNγ.
(C) qRT-PCR of IL-8 mRNA levels and (D) ELISA of IL-8 cytokine release in OC cells
incubated with 50 ng/mL IFNγ for up to 48 hours. The values represent the mean +/-SE
(n=4); an asterisk denotes a statistically significant (* p<0.05) change compared to
untreated (UT) cells.
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Figure 2: IFNγ induces STAT1 signaling in OC cells.
Real time qRT-PCR of PD-L1 and STAT1 mRNA in SKOV3 (A) and OVCAR3 (B) cells
incubated with 50 ng/mL IFNγ. Western blotting of PD-L1, STAT1, Tyr701-pSTAT1,
Ser727-pSTAT1 and control actin analyzed in whole cell extracts (WCE) of SKOV3 (C)
and OVCAR3 (D) cells incubated with 50 ng/mL IFNγ. The values represent the mean
+/-SE (n=3); an asterisk denotes a statistically significant (* p<0.05) change compared to
control untreated (UT) cells.
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Figure 3: IFNγ-induced IL-8 expression is dependent on JAK1.
(A) Western blotting of JAK1 and control actin levels analyzed in whole cell extracts
(WCE) from SKOV3 cells transfected with JAK1 and control siRNA. (B) Densitometric
evaluation of JAK1 protein levels shown in panel A. The JAK1 densities were
normalized to actin. (C) Quantitative RT-PCR of IL-8 mRNA in IFNγ-treated SKOV3
cells transfected with JAK1 and control siRNA. The values represent the mean +/-SE
(n=3); an asterisk denotes a statistically significant (* p<0.05) change compared to cells
transfected with control siRNA.
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Figure 4: IFNγ-induced IL-8 expression is dependent on STAT1.
(A) Western blotting of STAT1 and actin levels analyzed in WCE from SKOV3 cells
transfected with STAT1 and control siRNA. (B) Densitometric evaluation of STAT1
protein levels shown in panel A. The STAT1 densities were normalized to actin. (C) RTPCR of IL-8 mRNA in IFNγ-treated SKOV3 cells transfected with STAT1 and control
siRNA. The values represent the mean +/-SE (n=3); an asterisk denotes a statistically
significant (* p<0.05) change compared to cells transfected with control siRNA.
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Figure 5. IFNγ-induced IL-8 expression is dependent on p65 NFB.
(A) Western blotting of p65 NFB and actin levels analyzed in WCE from SKOV3 cells
transfected with p65 NFB and control siRNA. (B) Densitometric evaluation of p65
NFB protein levels shown in panel A. The p65 densities were normalized to actin.
(C) RT-PCR of IL-8 mRNA in IFNγ-treated SKOV3 cells transfected with p65 NFB
and control siRNA. The values represent the mean +/-SE (n=3); an asterisk denotes a
statistically significant (* p<0.05) change compared to cells transfected with control
siRNA.
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Figure 6. IFNγ induces K314/315 ac-p65 and Ser727 p-STAT1 recruitment to IL-8
promoter.
(A) Western analysis of p65, K314/315 ac-p65, STAT1, Ser727 pSTAT1, and control
actin in WCE of SKOV3 cells incubated with 50 ng/mL IFNγ. (B) Schematic illustration
of STAT1 and NFB binding sites in human IL-8 promoter. (C) Recruitment of p65,
K314/315 ac-p65, STAT1, and Ser727 pSTAT1 to STAT1 and NFB binding sites in
IL-8 promoter. The data are presented as fold-difference in occupancy of the
particular protein at the particular locus compared with the negative control human
IGX1A (SA Biosciences) locus, which does not contain any transcription factors binding
sites. The values represent the mean +/-SE (n=3); an asterisk denotes a statistically
significant (* p<0.05) change compared with untreated cells.
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Figure 7: Neutralization of IFNγ-induced IL-8 inhibits migration of OC cells.
(A) SKOV3 cells were incubated 24 h with IFNγ (0 and 50 ng/mL) in the presence of IL8 neutralizing monoclonal IgG1 (2 g//mL) or control IgG1 (2 g//mL), and cell
migration was evaluated by counting the number of migrated cells through the
membrane. Magnification: 10X. (B) Images from panel A were quantified using ImageJ
software. The results are presented as mean +/-SE, n=4.
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Figure 8: Flow cytometry analysis of surface PD-L1 expression in IFNγ-treated OC
cells.
(A) Histogram of PD-L1 surface expression in IFNγ-treated SKOV3 cells, illustrating the
fluorescence intensity (horizontal axis) against the number of events detected (vertical
axis). Cells incubated with isotype-matched control IgG are plotted in green; untreated
cells are plotted in blue, and IFNγ (50 ng/mL, 48 h)-treated cells are plotted in red. (B)
Relative fold surface expression of PD-L1 in untreated cells vs. IFNγ-treated cells
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Figure 9: IFNγ induced PD-L1 expression in OC cells is dependent on JAK1.
Gene expression of JAK1 (A) and PD-L1 (B) measured by RT-PCR in SKOV3 cells
transfected with control and JAK1 siRNA and incubated with 50 ng/mL IFNγ.
(C) Western blotting of JAK1, PD-L1, Tyr701- pSTAT1, Ser727-pSTAT1, STAT1, and
control actin analyzed in WCE of SKOV3 cells transfected with control and JAK1
siRNA and incubated with 50 ng/mL IFNγ. The values represent the mean +/-SE (n=3);
an asterisk denotes a statistically significant (* p<0.05) change compared to cells
transfected with control siRNA.
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Figure 10: IFNγ induced PD-L1 expression in OC cells is dependent on STAT1.
Gene expression of STAT1 (A) and PD-L1 (B) measured by RT-PCR in SKOV3 cells
transfected with control and STAT1 siRNA and incubated with 50 ng/mL IFNγ. (C)
Western blotting of STAT1, PD-L1 and actin analyzed in WCE of SKOV3 cells
transfected with control and STAT1 siRNA and incubated with 50 ng/mL IFNγ. (D)
Densitometric evaluation of PD-L1 protein levels shown in panel C; PD-L1 densities
were normalized to actin and expressed as % compared with control UT cells. The values
represent the mean +/-SE (n=3); an asterisk denotes a statistically significant (* p<0.05)
change compared to cells transfected with control siRNA.
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Figure 11: IFNγ induced PD-L1 expression in OC cells is dependent on IRF1.

Gene expression of IRF1 (A) and PD-L1 (B) measured by RT-PCR in SKOV3 cells
transfected with control and IRF1 siRNA and incubated with 50 ng/mL IFNγ. (C)
Western blotting of IRF1, PD-L1 and actin analyzed in WCE of SKOV3 cells transfected
with control and IRF1 siRNA and incubated with 50 ng/mL IFNγ. (D) Densitometric
evaluation of PD-L1 protein levels shown in panel C; PD-L1 densities were normalized
to actin and expressed as % compared with control UT cells. The values represent the
mean +/-SE (n=3); an asterisk denotes a statistically significant (* p<0.05) change
compared to cells transfected with control siRNA.

34

Figure 12: IFNγ induces PD-L1 promoter acetylation and occupancy by STAT1,
Ser727-pSTAT1 and IRF1 in OC cells.
(A) Schematic illustration of STAT1 and IRF1 binding sites in human PD-L1 promoter.
Occupancy of STAT1 (B) and IRF1 (C) binding sites in human PD-L1 promoter by
STAT1, Ser727-pSTAT1, IRF1, histone H3 and ac-histone H3 analyzed by chromatin
immunoprecipitation (ChIP) in SKOV3 cells incubated with 50 ng/mL IFNγ. The data
are presented as fold difference in occupancy of the particular protein at the particular
locus compared with the negative control human IGX1A (SA Biosciences) locus, which
does not contain any transcription factors binding sites. The values represent the mean ±
SE (n = 3); an asterisk denotes a statistically significant (* p < 0.05) change compared
with UT cells.
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